Mexico: Proven commercial use required for trademarks to achieve acquired distinctiveness

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: Proven commercial use required for trademarks to achieve acquired distinctiveness

Sponsored by

olivares-400px.jpg

On August 10, 2018 several modifications to the Mexican Industrial Property Law entered into force, resulting in some new IP figures being recognised in Mexico.

One of the new legal concepts included in the Law is 'acquired distinctiveness,' more commonly known as 'secondary meaning', which allows the registration of trademarks that can be considered as not initially distinctive, but owing to their commercial use have acquired distinctiveness.

However, these modifications still need to be complemented with regulation and are yet to be published in the Official Gazette.

In light of this there are no clear guidelines to determine the evidence required to support an application for a trademark filed based on acquired distinctiveness, and so it is not clear how The Mexican Institute of Industrial Property (IMPI) will examine these applications when filed.

In order to be able to demonstrate that a trademark has acquired distinctiveness it is necessary to prove that it has been used in the market and that consumers recognise the trademark in relation to the goods and/or services that it distinguishes. This is to ensure that the trademark complies with its main requisite, i.e. that it is sufficiently distinctive to enable its goods/services to be distinguished from others in the market.

Factors that can support the distinctiveness of the trademark in the market include:

  • surveys;

  • the date of first use of the mark in Mexico;

  • the period of time of continued use and advertisement of the trademark in Mexico;

  • the volume of sales of the goods/services identified with the trademark during the last three years.

In any case, until the regulations to the industrial property law are published in the Official Gazette, it will be necessary to meet with examiners to determine whether or not this evidence is sufficient to obtain a favourable resolution from the authorities.

caraza-wilma.jpg

Wilma Caraza


Olivares

Pedro Luis Ogazón No 17

Col San Angel

01000 México DF

Tel: +5255 53 22 30 00

Fax: +5255 53 22 30 01

olivlaw@olivares.com.mx

www.olivares.com.mx


more from across site and SHARED ros bottom lb

More from across our site

Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Gift this article